Covid19 vaccine : Sputnik V provides 90% protection against Delta Variant – Scientist
Viral vector and mRNA vaccines, including Russia’s Sputnik V, provide enough protection against the new Delta strain of the coronavirus, Head of the Novosibirsk State University’s Laboratory and corresponding member of the Russian Academy of Sciences (RAS) Sergey Netesov told Sputnik.
“According to data from the UK, the US and other countries, mRNA and vector vaccines, including our Sputnik V, protect against it [the Delta variant], albeit to a lesser extent, but they do protect against it. They offered 95 per cent protection against the initial strain and now they give 90% protection against the ‘delta’ variant,” Netesov said.
At the end of June, Vladimir Gushchin, the head of the population variability mechanisms laboratory of the Gamaleya research center that developed the Sputnik V vaccine, said that the Russian shots guarantee almost 100 per cent protection against severe and fatal cases of COVID-19 caused by the Delta strain. Russia became the first country in the world to register a vaccine against the coronavirus, dubbed Sputnik V, in August 2020.
The interval between the first and second Sputnik V COVID-19 vaccine shots can be extended to 180 days, the Russian Direct Investment Fund (RDIF) said Friday, citing a better immune response. The remarks came after the Philippines Food and Drug Administration stated this week that Moscow’s Gamaleya Institute had requested the country to extend the gap between the 2 shots to 90 days from 21 days that the vaccine was being administered.
The head of the Philippines’ Food and Drug Administration (FDA) Rolando Enrique Domingo announced a 42-day gap between Sputnik V doses stating that there was no issue with delaying the second dose. Russia’s Sputnik V is being manufactured by Gamaleya Research Institute of Epidemiology and Microbiology in collaboration with the RDIF.
Earlier last week, some countries such as Argentina and Kazakistan decided to widen the 2-shot gap of the Russian developed vaccine, quoting RDIF’s take on better immune response against the novel coronavirus.